Innovation Validation Call 2027

Opened

Programme Category

EU Competitive Programmes

Programme Name

Horizon Europe (2021-2027)

Programme Description

Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.

Programme Details

Identifier Code

EIT Health 26-28

Call

Innovation Validation Call 2027

Summary

EIT Health’s Innovation Validation Call 2027 supports innovative digital and AI–powered medical technologies that are ready for real-world clinical validation and are approaching market launch. This call addresses the funding gap for solutions that need to run clinical studies and collect evidence to demonstrate safety and efficacy, apply for regulatory approval and prepare for market commercialisation.

Detailed Call Description

The Innovation Validation Call invites organisations from across the Knowledge Triangle (Industry, Education and Research) to submit applications for funding for collaborative projects focused on patient-centric digital health solutions starting at Innovation Maturity Level (IML) 6 – Solution Validation.These innovations are typically at the stage of running pivotal clinical trials and generating real-world evidence that will be instrumental for the market authorisation (e.g. obtaining the CE mark or equivalent) and building commercial readiness of the solution. Solutions must go beyond the state-of-the-art and leverage digital and AI technology to address a critical, unmet healthcare need. They should deliver tangible health outcomes to patients across one or more stages of the patient care pathway, whether through screening, diagnosis, treatment and/or monitoring. Solutions must meet the definition of a Digital medical devices or in-vitro diagnostics device
as defined in the European regulations MDR 2017/745 and IVDR 2017/746.

EIT Health’s Innovation Validation Call is specifically designed to bridge the late-stage valley of death and accelerate the clinical validation of promising digital- and AI-powered healthcare innovations such as digital medical devices and diagnostic solutions.

EIT Health will co-fund collaborative consortium projects aiming to accelerate the clinical validation and market launch of patient-centric digital-and AI-powered health by supporting the following key activities:

  • Pivotal Clinical Trials: Execution of trials designed to conclusively demonstrate safety and efficacy through statistically valid outcomes.
  • Advanced Solution & IP Development: Final verification testing, IP protection strategies, minor iterations and completion of technical file.
  • Regulatory Approval:Preparation and submission of the technical file and scientific or clinical evidence dossier for regulatory authorisation.
  • Market Launch: Detailed market analysis, engagement of stakeholders, pricing and business model, and go-to-market strategy.

The solution must be at an Innovation Maturity Level (IML) of 6 (Initial Clinical Trials), with the aim to reach IML 7 (Solution Validation) by the end of the project.

Call Total Budget

€5.100.000

Financing percentage by EU or other bodies / Level of Subsidy or Loan

EIT Health will fund up to 50% of the total project budget, up to a total grant funding amount of €850.000 per project. The commercialising entity must sign a Financial Sustainability Contribution Agreement and, in the case that it is a micro or small enterprise, must receive €400.000 – €500.000 of the grant.

Up to 6 projects may be awarded, subject to the quality of the proposals.

Eligible costs must follow those as set out in the Horizon Europe model grant agreement.

Solutions must have the potential to impact 150.000 EU patients/citizens.

Projects must not run longer than 20 months, with an effective start date on 01 May 2027 and maximum end date on 31 December 2028.

Thematic Categories

  • Health
  • Information and Communication Technologies
  • Research, Technological Development and Innovation

Eligibility for Participation

  • Businesses
  • Educational Institutions
  • Large Enterprises
  • Researchers/Research Centers/Institutions
  • Small and Medium Enterprises (SMEs)

Eligibility For Participation Notes

In accordance with the Horizon Europe Work Programme, to be eligible for funding, the applicant must be established in one of the eligible countries, i.e.:

  • the Member States of the European Union, including their outermost regions;
  • the Overseas Countries and Territories (OCTs) linked to the Member States;
  • countries associated to Horizon Europe;  or,
  • certain low- and middle-income countries.

Consortium composition

Consortia of at least two organisations from different countries representing at least two sides of the Knowledge Triangle (industry, research, education). A commercialising company must lead the project. Eligible solutions must be digital or AI-enabled medical devices (MDR/IVDR) at Innovation Maturity Level (IML) 6, aiming to reach IML 7 by project end.

Please refer to EIT Health’s Healthcare Innovation Cycle Framework for more information on the required Innovation Maturity Level for this call.

Call Opening Date

14/10/2026

Call Closing Date

13/01/2027

National Contact Point(s)

EIT Community RIS Hub Cyprus

Dr. Styliani Petroudi
EIT Community Officer Cyprus 

Email: cyprus@eitcommunity.eu

EU Contact Point

For general administrative queries, questions about the application platform, or technical issues with the submission process, please contact the EIT Health directly:
via email: calls@eithealth.eu – please include the call code: INNO_VALIDATION27 and your application reference code in the subject line of all correspondence.